HYDERABAD: India’s first indigenous vaccine Covaxin was successful in eliciting a robust immune response without any serious side effects during the Phase 1 studies conducted on 375 volunteers, Bharat Biotech said in a research article.
The company said most of the side effects seen during the study were mild and resolved successfully. “Only one serious adverse reaction was reported that was determined to be unrelated to vaccination,” the company said in the article published on medRxiv.org.
Read our coronavirus live blog for all the latest news and updates
Bharat Biotech also said Covaxin, code-named BBV152, is the first inactivated SARS-CoV-2 vaccine reportedly to induce a Th1-biased response. Th1 cells have antigen-specific receptors on their cell surface to help recognize foreign pathogens and protect the body from viruses and bacteria.
The company said most of the side effects seen during the study were mild and resolved successfully. “Only one serious adverse reaction was reported that was determined to be unrelated to vaccination,” the company said in the article published on medRxiv.org.
Read our coronavirus live blog for all the latest news and updates
Bharat Biotech also said Covaxin, code-named BBV152, is the first inactivated SARS-CoV-2 vaccine reportedly to induce a Th1-biased response. Th1 cells have antigen-specific receptors on their cell surface to help recognize foreign pathogens and protect the body from viruses and bacteria.
Neutralizing responses to homologous and heterologous SARS-CoV-2 strains were detected in all vaccinated individuals. Cell-mediated responses were biased towards a Th-1 phenotype, ”he said.
Covaxin, which is being developed by the Hyderabad-based vaccine maker in conjunction with the Indian Council of Medical Research (ICMR), is currently undergoing phase 3 efficacy studies with approximately 26,000 volunteers at 25 sites across the country.
The vaccine must be stored between 2 ° C and 8 ° C, which is compatible with all requirements of the national cold chain immunization program, the company said.